• Twenty-one patients with Parkinson's disease were studied because their low maintenance dosages of carbidopa-levodopa in the customary ratio of 1:10 provided less than the daily 75 mg of carbidopa believed nescessary to achievo full inhibition of extracerebral dopa decerboxylation. The dosage of carbidopa was increassd 2.5 times to between 75 and 150 mg daily, while the mean dosage of levodopa essentially was unchanged. The new carbidopa-levodopa ratio was 1:4. During 15 months, this treatment produced a moderate decrease in the severity of parkinsonism and a marked decrease in paripheral adverse reactions, without a significant increase in the central adverse effects of levodopa. It is concluded that increasing the dosage of carbidopa may be beneficial to patients with Parkinson's disease receiving less than 75 mg of carbidopa and 750 mg of levodopa daily.
Hoehn MM. Increased Dosage of Carbidopa in Patients With Parkinson's Disease Receiving Low Doses of Levodopa: A Pilot Study. Arch Neurol. 1980;37(3):146–149. doi:10.1001/archneur.1980.00500520044006
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: